文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

大手术后第7天之后的急性肾脏病:EPIS-AKI试验的二次分析

Acute kidney disease beyond day 7 after major surgery: a secondary analysis of the EPIS-AKI trial.
PubMed 文献 · Intensive Care Med · 2024-01-29
一句话结论大手术后约10%患者在第7天后发生急性肾脏病(AKD),多数无早期术后AKI,但早期AKI严重程度与持续时间与AKD风险增加相关。

这项国际前瞻性观察性多中心研究纳入9510例无既往慢性肾脏病(CKD)的大手术患者,主要终点为幸存者第7天或之后新发估算肾小球滤过率(eGFR)<60 ml/min/1.73 m2的急性肾脏病(AKD)发生率。940例(9.9%)发生AKD,其中34.1%曾出现早期术后急性肾损伤(AKI)。AKD发生率随早期术后AKI严重程度(KDIGO 1级19.1%、2级24.5%、3级34.3%,P<0.001)和持续时间(一过性15.5% vs 持续性38.3%,P<0.001)显著升高。早期术后AKI对AKD的独立比值比为2.64(95%CI 2.21-3.15)。在663例既往CKD患者中,第90天42例(6.3%)CKD恶化,其中合并早期AKI者CKD进展率为11.6%。

要点

  • 大手术后第7天及以后AKD发生率为9.9%(940/9510),多数(65.9%)没有早期术后AKI发作。
  • 早期术后AKI严重程度越高,AKD发生率越高:KDIGO 1级19.1%、2级24.5%、3级34.3%(P<0.001)。
  • 早期术后AKI持续时间与AKD相关:一过性AKI后AKD 15.5% vs 持续性AKI后38.3%(P<0.001)。
  • 早期术后AKI是AKD的独立危险因素,OR 2.64(95%CI 2.21-3.15);其他独立危险因素包括围术期肾毒性药物暴露和术后肺炎。
  • 既往CKD患者中,第90天CKD恶化率6.3%(42/663);合并早期AKI者CKD进展率11.6%。

适用人群与场景

  • 接受大手术的患者,来自国际前瞻性观察性多中心研究。
  • 主要分析纳入9510例无既往CKD的患者;另分析663例既往CKD患者。

诊断标准与关键阈值

  • AKD定义:第7天或之后新发eGFR <60 ml/min/1.73 m2(见于幸存者)。
  • 早期术后AKI定义:大手术后72小时内发生的AKI。
  • 早期术后AKI按KDIGO 1、2、3级分层;按持续时间分为一过性与持续性。

研究设计与关键结果

  • 研究类型:国际前瞻性观察性多中心研究(EPIS-AKI试验的二次分析)。
  • 主要终点:9510例无既往CKD患者中,940例(9.9%)在第7天后发生AKD,其中34.1%经历过早期术后AKI。
  • AKD发生率随早期术后AKI严重程度增加:KDIGO 1级19.1%、KDIGO 2级24.5%、KDIGO 3级34.3%(P<0.001)。
  • AKD发生率随早期术后AKI持续时间增加:一过性AKI 15.5% vs 持续性AKI 38.3%(P<0.001)。
  • 早期术后AKI对AKD的独立OR为2.64(95%CI 2.21-3.15)。
  • 其他独立危险因素:围术期肾毒性药物暴露、术后肺炎。
  • 既往CKD患者663例中,第90天42例(6.3%)CKD恶化;合并早期AKI者CKD进展率11.6%。

证据类型、等级与局限

  • 证据类型:国际前瞻性观察性多中心研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 大手术后第7天及以后仍需关注AKD,即使患者未发生早期术后AKI(多数AKD患者无早期AKI)。
  • 早期术后AKI的严重程度和持续时间与后续AKD风险增加相关,早期术后AKI为AKD的独立危险因素(OR 2.64,95%CI 2.21-3.15)。
  • 围术期肾毒性药物暴露和术后肺炎为AKD的独立危险因素。
  • 既往CKD患者大手术后应关注CKD进展,合并早期AKI者第90天CKD进展率为11.6%。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Acute kidney disease (AKD) is a significant health care burden worldwide. However, little is known about this complication after major surgery.

METHODS: We conducted an international prospective, observational, multi-center study among patients undergoing major surgery. The primary study endpoint was the incidence of AKD (defined as new onset of estimated glomerular filtration rate (eCFR) < 60 ml/min/1.73 m2 present on day 7 or later) among survivors. Secondary endpoints included the relationship between early postoperative acute kidney injury (AKI) (within 72 h after major surgery) and subsequent AKD, the identification of risk factors for AKD, and the rate of chronic kidney disease (CKD) progression in patients with pre-existing CKD.

RESULTS: We studied 9510 patients without pre-existing CKD. Of these, 940 (9.9%) developed AKD after 7 days of whom 34.1% experiencing an episode of early postoperative-AKI. Rates of AKD after 7 days significantly increased with the severity (19.1% Kidney Disease Improving Global Outcomes [KDIGO] 1, 24.5% KDIGO2, 34.3% KDIGO3; P < 0.001) and duration (15.5% transient vs 38.3% persistent AKI; P < 0.001) of early postoperative-AKI. Independent risk factors for AKD included early postoperative-AKI, exposure to perioperative nephrotoxic agents, and postoperative pneumonia. Early postoperative-AKI carried an independent odds ratio for AKD of 2.64 (95% confidence interval [CI] 2.21-3.15). Of 663 patients with pre-existing CKD, 42 (6.3%) had worsening CKD at day 90. In patients with CKD and an episode of early AKI, CKD progression occurred in 11.6%.

CONCLUSION: One in ten major surgery patients developed AKD beyond 7 days after surgery, in most cases without an episode of early postoperative-AKI. However, early postoperative-AKI severity and duration were associated with an increased rate of AKD and early postoperative-AKI was strongly associated with AKD independent of all other potential risk factors.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Meersch M, Weiss R, Strauß C, et al. Acute kidney disease beyond day 7 after major surgery: a secondary analysis of the EPIS-AKI trial. Intensive Care Med. 2024. PMID: 38285051. doi:10.1007/s00134-023-07314-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。